Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Background: It is unknown whether screening for atrial fibrillation and subsequent treatment with anticoagulants if atrial fibrillation is detected can prevent stroke. Continuous electrocardiographic monitoring using an implantable loop recorder (ILR) can facilitate detection of asymptomatic atrial fibrillation episodes. We aimed to investigate whether atrial fibrillation screening and use of anticoagulants can prevent stroke in individuals at high risk. Methods: We did a randomised controlled trial in four centres in Denmark. We included individuals without atrial fibrillation, aged 70–90 years, with at least one additional stroke risk factor (ie, hypertension, diabetes, previous stroke, or heart failure). Participants were randomly assigned in a 1:3 ratio to ILR monitoring or usual care (control) via an online system in permuted blocks with block sizes of four or eight participants stratified according to centre. In the ILR group, anticoagulation was recommended if atrial fibrillation episodes lasted 6 min or longer. The primary outcome was time to first stroke or systemic arterial embolism. This study is registered with ClinicalTrials.gov, NCT02036450. Findings: From Jan 31, 2014, to May 17, 2016, 6205 individuals were screened for inclusion, of whom 6004 were included and randomly assigned: 1501 (25·0%) to ILR monitoring and 4503 (75·0%) to usual care. Mean age was 74·7 years (SD 4·1), 2837 (47·3%) were women, and 5444 (90·7%) had hypertension. No participants were lost to follow-up. During a median follow-up of 64·5 months (IQR 59·3–69·8), atrial fibrillation was diagnosed in 1027 participants: 477 (31·8%) of 1501 in the ILR group versus 550 (12·2%) of 4503 in the control group (hazard ratio [HR] 3·17 [95% CI 2·81–3·59]; p<0·0001). Oral anticoagulation was initiated in 1036 participants: 445 (29·7%) in the ILR group versus 591 (13·1%) in the control group (HR 2·72 [95% CI 2·41–3·08]; p<0·0001), and the primary outcome occurred in 318 participants (315 stroke, three systemic arterial embolism): 67 (4·5%) in the ILR group versus 251 (5·6%) in the control group (HR 0·80 [95% CI 0·61–1·05]; p=0·11). Major bleeding occurred in 221 participants: 65 (4·3%) in the ILR group versus 156 (3·5%) in the control group (HR 1·26 [95% CI 0·95–1·69]; p=0·11). Interpretation: In individuals with stroke risk factors, ILR screening resulted in a three-times increase in atrial fibrillation detection and anticoagulation initiation but no significant reduction in the risk of stroke or systemic arterial embolism. These findings might imply that not all atrial fibrillation is worth screening for, and not all screen-detected atrial fibrillation merits anticoagulation. Funding: Innovation Fund Denmark, The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation, Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, The AFFECT-EU Consortium (EU Horizon 2020), Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat, and Medtronic.

OriginalsprogEngelsk
TidsskriftThe Lancet
Vol/bind398
Udgave nummer10310
Sider (fra-til)1507-1516
Antal sider10
ISSN0140-6736
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
The LOOP Study is supported by Innovation Fund Denmark (12-135225), The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation (11-04-R83-A3363-22625), Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, The AFFECT-EU Consortium (Horizon 2020, grant number 847770-AFFECT-EU), L?ge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat, and an unrestricted grant from Medtronic. We thank Dan Atar (University of Oslo and Department of Cardiology B, Oslo University Hospital Ullev?l, Oslo, Norway), Gregory Y H Lip (The University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK), and M?rten Rosenqvist (Karolinska Institutet and Danderyd Hospital, Stockholm, Sweden), for assisting the study with their expertise in the study's international advisory committee. We thank the research nurses and other colleagues in the Departments of Cardiology at Rigshospitalet, Bispebjerg and Frederiksberg Hospital, Zealand University Hospital, and Odense University Hospital who assisted with study procedures.

Funding Information:
JHS is a member of Medtronic advisory boards and has received speaker honoraria and research grants from Medtronic in relation to this work and outside the submitted work. SZD is a part-time employee of Vital Beats outside the submitted work. DWK is a member of a Medtronic advisory board on stroke and has received speaker honoraria and travel grants from Medtronic, St Jude Medical, and Boehringer Ingelheim, outside the submitted work. AB reports research grants from The Region of Southern Denmark and The Region of Zealand, and Theravance; speaker honoraria from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb; and a travel grant from Biotronik, outside the submitted work. JBN is an employee of Regeneron Pharmaceuticals, outside the submitted work. AGH is an employee of Acesion Pharma, outside the submitted work. KJH reports travel and educational grants from Medtronic, Abbott, and BIOTRONIK; and speaker honoraria from Boehringer Ingelheim, outside the submitted work. LK reports speaker honoraria from Novo, AstraZeneca, Novartis, and Boehringer Ingelheim, outside the submitted work. All other authors declare no competing interests.

Funding Information:
The LOOP Study is supported by Innovation Fund Denmark (12-135225), The Research Foundation for the Capital Region of Denmark, The Danish Heart Foundation (11-04-R83-A3363-22625), Aalborg University Talent Management Program, Arvid Nilssons Fond, Skibsreder Per Henriksen, R og Hustrus Fond, The AFFECT-EU Consortium (Horizon 2020, grant number 847770-AFFECT-EU), Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat, and an unrestricted grant from Medtronic. We thank Dan Atar (University of Oslo and Department of Cardiology B, Oslo University Hospital Ullevål, Oslo, Norway), Gregory Y H Lip (The University of Liverpool and Liverpool Heart and Chest Hospital, Liverpool, UK), and Mårten Rosenqvist (Karolinska Institutet and Danderyd Hospital, Stockholm, Sweden), for assisting the study with their expertise in the study's international advisory committee. We thank the research nurses and other colleagues in the Departments of Cardiology at Rigshospitalet, Bispebjerg and Frederiksberg Hospital, Zealand University Hospital, and Odense University Hospital who assisted with study procedures.

Publisher Copyright:
© 2021 Elsevier Ltd

ID: 283735839